Open AccessAbstract CT290: Ibrutinib-rituximab versus placebo-rituximab for first-line treatment of follicular lymphoma: PERSPECTIVE, a randomized phase 3 study
Author(s) -
Nathan Fowler,
Ian W. Flinn,
Simon Rule,
Robert Chen,
Long Kwei,
Alvina D. Chu,
Leo I. Gordon
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct290
Subject(s) - ibrutinib , rituximab , medicine , follicular lymphoma , oncology , idelalisib , placebo , progression free survival , lymphoma , chemotherapy , chronic lymphocytic leukemia , leukemia , pathology , alternative medicine